In addition to establishing itself as a recognized leader in its field, SENS Foundation is committed to ensuring mature operational and financial management from the day of its launch, and has put together a senior management team to reflect that commitment.
Mike specializes in business development consulting. He currently serves as CEO of Genomic Systems, a company developing an anti-metastatic antibody for a wide range of cancers, and as officer and advisor for companies involved in genomic analysis, anti-aging research, vaccines and delivery technologies, research management systems, and genetic sequencing. Previously, Mike was Director of Corporate Development for MedImmune, Inc., serving the MedImmune Vaccines unit formerly known as Aviron. He came to Aviron a few years after having licensed the company its core FluMist™ technology from the University of Michigan, where he served as the University's Intellectual Property Counsel through the Nineties. Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful start-ups. He received his JD from the University of Michigan in 1990.
Aubrey is a biomedical gerontologist based in Cambridge, UK, and has most recently served as Chairman and Chief Science Officer of the Methuselah Foundation, a 501(c)(3) non-profit charity dedicated to combating the aging process. He is also the Editor-in-Chief of Rejuvenation Research, the world's only peer-reviewed journal focused on intervention in aging. His research interests focus on the accumulating, and eventually pathogenic, molecular and cellular side-effects of metabolism ("damage"). This "damage" constitutes mammalian aging and Aubrey's work seeks to design the interventions necessary for its repair and/or obviation. He has developed a potentially comprehensive plan for such repair, termed Strategies for Engineered Negligible Senescence (SENS), which breaks the aging problem down into seven major classes of damage and identifies detailed approaches to addressing each one. A key aspect of SENS is its potential to extend healthy lifespan without limit, even with repair processes which remain imperfect, as the repair only needs to approach perfection rapidly enough to keep the overall level of damage below pathogenic levels. Aubrey has termed this required rate of improvement of repair therapies, "longevity escape velocity". In 2007 Aubrey published his book, Ending Aging, bringing his ideas to a wider audience.
Sarah was most recently acting Director of the UK charity, the BioGerontology Research Foundation. She was previously employed as COO of the UK political think-tank, Demos, with responsibilities including financial management and accounting, HR, business infrastructure, and strategic development. She also co-authored a global survey of design practices in public sector service delivery, working with a team from PriceWaterhouseCoopers. In the 1990s she spent several years as a business and IT consultant with Andersen Consulting (now Accenture), working on a variety of projects from systems analysis to the streamlining of the new business acquisition procedures for the company's EMEAI operations. She has a Bachelor's Degree in Law, from the University of Oxford, and another in Theoretical Physics, from Imperial College London, where she also built a prototype web portal for the European grid computing network of the Large Hadron Collider. Her postgraduate studies include a Master's Degree in Social Anthropology from the University of Manchester, specializing in the nature of cultural misappropriation in Western subcultures, and a PhD in Theoretical Physics from Imperial College London, covering the quantum and relativistic properties of black holes in discrete spacetimes.
Kevin’s biographical details can be found on the Interim Board page.
Jeff gained his Bachelor's Degree in Electrical Engineering from the University of Michigan, and has over twenty years of engineering and management experience. Over the past sixteen years he has been involved in entrepreneurial ventures, including three years in Silicon Valley, developing a web portal business and working with venture capitalists. His engineering qualification has been supplemented by two years of philosophy studies with an emphasis on AI research, again at the University of Michigan, in addition to more recent, in-depth involvement with molecular biology and biogerontology. Jeff is the founder and Chief Engineer of Muse Technologies, an engineering consulting and systems integration company based in Ann Arbor, MI, which is currently engaged in an NIH-funded research project with the University of Michigan. He is the Chief Engineer of Halcyon Molecular, and has also worked as a research engineer, supporting the ATLAS upgrade to the CERN Accelerator, and as Program Manager for Virtio, a startup company developing simulation software for embedded systems. Since 2005 Jeff worked with the Methuselah Foundation, most recently as Executive Director of SENS.
